OBJECTIVE: To determine whether changes in standard and novel risk factors during the Actos Now for Prevention of Diabetes trial explained the slower rate of carotid intima media thickness (CIMT) progression with pioglitazone treatment in persons with prediabetes. METHODS AND RESULTS: CIMT was measured in 382 participants at the beginning and up to 3 additional times during follow-up of the Actos Now for Prevention of Diabetes trial. During an average follow-up of 2.3 years, the mean unadjusted annual rate of CIMT progression was significantly (P=0.01) lower with pioglitazone treatment (4.76×10(-3) mm/year; 95% CI: 2.39×10(-3)-7.14×10(-3) mm/year) compared with placebo (9.69×10(-3) mm/year; 95% CI: 7.24×10(-3)-12.15×10(-3) mm/year). High-density lipoprotein cholesterol, fasting and 2-hour glucose, HbA(1c), fasting insulin, Matsuda insulin sensitivity index, adiponectin, and plasminogen activator inhibitor-1 levels improved significantly with pioglitazone treatment compared with placebo (P<0.001). However, the effect of pioglitazone on CIMT progression was not attenuated by multiple methods of adjustment for traditional, metabolic, and inflammatory risk factors and concomitant medications, and was independent of changes in risk factors during pioglitazone treatment. CONCLUSIONS:Pioglitazone slowed progression of CIMT, independent of improvement in hyperglycemia, insulin resistance, dyslipidemia, and systemic inflammation in prediabetes. These results suggest a possible direct vascular benefit of pioglitazone.
RCT Entities:
OBJECTIVE: To determine whether changes in standard and novel risk factors during the Actos Now for Prevention of Diabetes trial explained the slower rate of carotid intima media thickness (CIMT) progression with pioglitazone treatment in persons with prediabetes. METHODS AND RESULTS:CIMT was measured in 382 participants at the beginning and up to 3 additional times during follow-up of the Actos Now for Prevention of Diabetes trial. During an average follow-up of 2.3 years, the mean unadjusted annual rate of CIMT progression was significantly (P=0.01) lower with pioglitazone treatment (4.76×10(-3) mm/year; 95% CI: 2.39×10(-3)-7.14×10(-3) mm/year) compared with placebo (9.69×10(-3) mm/year; 95% CI: 7.24×10(-3)-12.15×10(-3) mm/year). High-density lipoprotein cholesterol, fasting and 2-hour glucose, HbA(1c), fasting insulin, Matsuda insulin sensitivity index, adiponectin, and plasminogen activator inhibitor-1 levels improved significantly with pioglitazone treatment compared with placebo (P<0.001). However, the effect of pioglitazone on CIMT progression was not attenuated by multiple methods of adjustment for traditional, metabolic, and inflammatory risk factors and concomitant medications, and was independent of changes in risk factors during pioglitazone treatment. CONCLUSIONS:Pioglitazone slowed progression of CIMT, independent of improvement in hyperglycemia, insulin resistance, dyslipidemia, and systemic inflammation in prediabetes. These results suggest a possible direct vascular benefit of pioglitazone.
Authors: Z Chen; S Ishibashi; S Perrey; T Gotoda; T Kitamine; Y Tamura; H Okazaki; N Yahagi; Y Iizuka; F Shionoiri; K Ohashi; K Harada; H Shimano; R Nagai; N Yamada Journal: Arterioscler Thromb Vasc Biol Date: 2001-03 Impact factor: 8.311
Authors: H N Hodis; W J Mack; R A Lobo; D Shoupe; A Sevanian; P R Mahrer; R H Selzer; C R Liu Cr; C H Liu Ch; S P Azen Journal: Ann Intern Med Date: 2001-12-04 Impact factor: 25.391
Authors: Ralph A DeFronzo; Devjit Tripathy; Dawn C Schwenke; MaryAnn Banerji; George A Bray; Thomas A Buchanan; Stephen C Clement; Robert R Henry; Howard N Hodis; Abbas E Kitabchi; Wendy J Mack; Sunder Mudaliar; Robert E Ratner; Ken Williams; Frankie B Stentz; Nicolas Musi; Peter D Reaven Journal: N Engl J Med Date: 2011-03-24 Impact factor: 91.245
Authors: Theodore Mazzone; Peter M Meyer; Steven B Feinstein; Michael H Davidson; George T Kondos; Ralph B D'Agostino; Alfonso Perez; Jean-Claude Provost; Steven M Haffner Journal: JAMA Date: 2006-11-13 Impact factor: 56.272
Authors: Z Levi; A Shaish; N Yacov; H Levkovitz; S Trestman; Y Gerber; H Cohen; A Dvir; R Rhachmani; M Ravid; D Harats Journal: Diabetes Obes Metab Date: 2003-01 Impact factor: 6.577
Authors: Steven E Nissen; Stephen J Nicholls; Kathy Wolski; Richard Nesto; Stuart Kupfer; Alfonso Perez; Horacio Jure; Robert De Larochellière; Cezar S Staniloae; Kreton Mavromatis; Jacqueline Saw; Bo Hu; A Michael Lincoff; E Murat Tuzcu Journal: JAMA Date: 2008-03-31 Impact factor: 56.272
Authors: Anny H Xiang; Howard N Hodis; Miwa Kawakubo; Ruth K Peters; Siri L Kjos; Aura Marroquin; Jose Goico; Cesar Ochoa; Chao-Ran Liu; Ci-Hua Liu; Thomas A Buchanan Journal: Atherosclerosis Date: 2007-12-04 Impact factor: 5.162
Authors: Alice Liu; Fahim Abbasi; Sun H Kim; Danit Ariel; Cindy Lamendola; James Cardell; Shiming Xu; Shailja Patel; Vanessa Tomasso; Hafasa Mojaddidi; Kaylene Grove; Philip S Tsao; Clete A Kushida; Gerald M Reaven Journal: Am J Cardiol Date: 2017-01-25 Impact factor: 2.778
Authors: Melanie J Davies; David A D'Alessio; Judith Fradkin; Walter N Kernan; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Apostolos Tsapas; Deborah J Wexler; John B Buse Journal: Diabetologia Date: 2018-12 Impact factor: 10.122
Authors: Silvio E Inzucchi; Catherine M Viscoli; Lawrence H Young; Karen L Furie; Mark Gorman; Anne M Lovejoy; Samuel Dagogo-Jack; Faramarz Ismail-Beigi; Mary T Korytkowski; Richard E Pratley; Gregory G Schwartz; Walter N Kernan Journal: Diabetes Care Date: 2016-07-27 Impact factor: 19.112